<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311034</url>
  </required_header>
  <id_info>
    <org_study_id>RC48-C004 NSCLC</org_study_id>
    <nct_id>NCT04311034</nct_id>
  </id_info>
  <brief_title>A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase Ib Study to Evaluate the Efficacy and Safety of RC48-ADC for Injection in Subjects With Advanced Non-small Cell Lung Cancer With HER2 Overexpression or HER2 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of RC48-ADC for injection in subjects with
      advanced non-small cell lung cancer with HER2 overexpression or HER2 mutation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate （ORR）</measure>
    <time_frame>15 months</time_frame>
    <description>Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>15 months</time_frame>
    <description>Disease Control Rate (DCR) was defined as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>15 months</time_frame>
    <description>Progression-free Survival (PFS) (median) was determined using the number of months measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression) of participants. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>15 months</time_frame>
    <description>Duration of response is the length of time that a tumor continues to respond to treatment without the cancer growing or spreading.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Overall survival, or OS, measures how long patients, who undergo a certain treatment regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The drug safety was assessed by investigator(s) according to NCI-CTCAE v4.03.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>RC48</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48</intervention_name>
    <description>Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.</description>
    <arm_group_label>RC48</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Voluntary signed informed consent.

          2. Male or female, Aged between 18 to 75 years.

          3. Predicted survival ≥ 12 weeks.

          4. According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed,
             cannot be surgically removed, locally advanced or metastatic NSCLC.

          5. Locally advanced or metastatic disease had failed at least one systemic treatment.

          6. Based on imaging judgment (RECIST 1.1) or clinical status, tumor progression during or
             after the last treatment before enrollment.

          7. HER2 protein overexpression (IHC 2+ or 3 +) or HER2 gene mutation (defined as exon 20
             mutation), the previous test results confirmed by the researchers, both research
             centers and major research centers can be acceptable.

          8. The researchers confirmed that the EGFR gene mutation status was negative or positive.
             For EGFR gene mutation-positive patients, one of the following is met: 1) T790M gene
             mutation negative, c-Met gene amplification negative and HER2 IHC 2+ or 3+ after
             first-generation EGFR-TKI drug resistance; 2) Third-generation EGFR-TKI treatment
             failed and HER2 IHC 2+ or 3+.

          9. Measurable lesion according to the RECIST 1.1.

         10. ECOG performance status score of 0 or 1.

         11. Adequate organ function: LVEF ≥ 50 %. Hemoglobin ≥ 9g/dL; ANC ≥ 1.5×10^9 /L; Platelets
             ≥ 100×10^9 /L; Total bilirubin ≤ 1.5×ULN; ALT, AST and ALP ≤ 2.5×ULN and ≤ 5 x ULN
             with hepatic metastasis; Serum creatinine ≤1.5×ULN, or CrCl ≥ 60mL/min; INR≤ 1.5× ULN,
             APTT≤ 1.5× ULN.

         12. For female subjects: should be surgically sterilized, postmenopausal, or agree to use
             a medically approved contraceptive (such as an intrauterine device, contraceptives, or
             condoms) during study treatment and within 6 months after the end of study, the blood
             pregnancy test within 7 days of study enrollment must be negative and must be
             non-lactating. Male subjects: Patients who should be surgically sterilized or agree to
             use a medically approved contraceptive during the study treatment period and within 6
             months after the end of the study.

         13. Willing and able to follow trial and follow-up procedures.

        Exclusion Criteria:

          1. Have used T-DM1 or participated in other HER2-ADC clinical studies.

          2. Received anti-tumor treatment 4 weeks before study administration, including
             chemotherapy (late toxicity chemotherapy was 6 weeks before study administration),
             radiotherapy (palliative local radiotherapy for bone metastases was 2 weeks before the
             study administration), biological therapy (small molecule targeted drugs were 8 days
             before the study administration) or immunotherapy, etc.

          3. Major surgery was performed within 4 weeks prior to study administration and did not
             fully recover.

          4. Other clinical trial drugs have been used within 4 weeks before the start of study
             administration.

          5. Live vaccine received within 4 weeks before the start of study administration.

          6. Have received anti-tumor Chinese medicine treatment within 2 weeks before the start of
             study administration.

          7. History of other malignant tumors within 5 years before signing the informed consent
             (except for non-melanoma skin cancer, cervical carcinoma in situ that has been
             effectively treated, or malignant tumors that have been resolved for more than 3 years
             after effective treatment and are considered to be cured) .

          8. Toxicity of previous anti-tumor treatment has not recovered to CTCAE (version 4.03)
             0-1, except for the following conditions: a. Hair loss; b. Pigmentation; c. Long-term
             toxicity caused by radiotherapy, which cannot be restored by the judgement of the
             investigator.

          9. Active central nervous system (CNS) metastasis and/or cancerous meningitis (subjects
             who have received brain metastasis treatment can participate in this study, provided
             that the condition is stable (no evidence of progression confirmed by imaging studies
             at least 4 weeks before study dosing, and all neurological symptoms have returned to
             baseline levels), no evidence of new or enlarged brain metastases, and discontinuation
             of steroid treatment at least 7 days before the first dose of trial treatment. This
             exception does not include cancerous meningitis, which should be excluded whether
             clinical status was stable).

         10. Diagnosed with HBsAg positive and HBV DNA positive, or HCV Ab positive, or HIV Ab
             positive.

         11. Severe arterial/venous thrombosis or cardio-cerebral vascular accidents occurred
             within 1 year before the study, such as deep vein thrombosis, pulmonary embolism,
             cerebral infarction, cerebral hemorrhage, myocardial infarction, etc.

         12. Active infections requiring systemic treatment.

         13. Other lung diseases required systemic treatment such as active tuberculosis,
             interstitial lung disease, etc.

         14. Uncontrolled systemic diseases such as diabetes, hypertension, cirrhosis, etc.

         15. Heart failure graded 3 or above by the NYHA.

         16. Pleural effusion, pericardial effusion, or peritoneal effusion with clinical symptoms
             that cannot be controlled by drainage or other methods.

         17. Mental illness or substance abuse known to have an impact on compliance with study
             requirements.

         18. Hypersensitivity or delayed allergic reaction to certain components of RC48-ADC or
             similar drugs.

         19. Any other disease, metabolic abnormality, abnormal physical examination or abnormal
             laboratory test, etc., based on the judgment of the investigator, it is reasonable to
             suspect that the patient has a certain disease or condition unsuitable for the
             research drug, or will affect the interpretation of the research results, or putting
             patients at high risk.

         20. Pregnant or lactating female or female / male who are planning to have children.

         21. Insufficient adherence to participate in this clinical study.

         22. Any other condition in which the investigator considers the patient unsuitable for
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianmin Fang</last_name>
    <phone>+8610-58075763</phone>
    <email>jianminfang@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caicun Zhou, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

